The Europe Advanced Therapy Medicinal Products CDMO Market would witness market growth of 16.5% CAGR during the forecast period (2022-2028).
The study of ATMPs is a field that is experiencing rapid expansion, though the majority of the developed products are still in the early stages of research. The ongoing combined trials and the possible development to treat severe chronic illnesses have led the probability of ATMPs being available on the market soon.
Targeted medicines have made it possible for there to be new trial techniques, and ATMPs could profit from these new trial methodologies to acquire early access. The majority of consumers also anticipate CDMOs to provide their knowledge in many processes even after manufacturing, such as during product launches.
This is primarily due to CDMO's growing customer base, which includes smaller biotech companies in addition to the major pharmaceutical corporations. In addition, many smaller biotech firms put a lot of effort into developing their drug pipelines without any manufacturing background. The early incorporation of smaller biotech enterprises' activities is thus made possible by using CDMOs' assistance in development and manufacturing operations.
The European Medicines Agency's Committee for Advanced Therapies (CAT) is tasked with evaluating marketing authorization (MA) requests for ATMPs and making scientific recommendations for the categorization of ATMPs, among other duties. The EMA and the European Commission released a joint action plan with the intention of streamlining procedures and better addressing the unique needs of ATMP developers. Such developments in the field of gene and cell therapy are propelling the growth of the advanced therapy medicinal products CDMO market in the coming years.
The Germany market dominated the Europe Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $749.2 million by 2028. The UK market is anticipated to grow at a CAGR of 15.5% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 17.3% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
The study of ATMPs is a field that is experiencing rapid expansion, though the majority of the developed products are still in the early stages of research. The ongoing combined trials and the possible development to treat severe chronic illnesses have led the probability of ATMPs being available on the market soon.
Targeted medicines have made it possible for there to be new trial techniques, and ATMPs could profit from these new trial methodologies to acquire early access. The majority of consumers also anticipate CDMOs to provide their knowledge in many processes even after manufacturing, such as during product launches.
This is primarily due to CDMO's growing customer base, which includes smaller biotech companies in addition to the major pharmaceutical corporations. In addition, many smaller biotech firms put a lot of effort into developing their drug pipelines without any manufacturing background. The early incorporation of smaller biotech enterprises' activities is thus made possible by using CDMOs' assistance in development and manufacturing operations.
The European Medicines Agency's Committee for Advanced Therapies (CAT) is tasked with evaluating marketing authorization (MA) requests for ATMPs and making scientific recommendations for the categorization of ATMPs, among other duties. The EMA and the European Commission released a joint action plan with the intention of streamlining procedures and better addressing the unique needs of ATMP developers. Such developments in the field of gene and cell therapy are propelling the growth of the advanced therapy medicinal products CDMO market in the coming years.
The Germany market dominated the Europe Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $749.2 million by 2028. The UK market is anticipated to grow at a CAGR of 15.5% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 17.3% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Oncology
- Cardiology
- Central Nervous System & Musculoskeletal
- Infectious Disease
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
By Product
- Gene Therapy
- Cell Therapy
- Tissue Engineered & Others
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Advanced Therapy Medicinal Products CDMO Market, by Indication
1.4.2 Europe Advanced Therapy Medicinal Products CDMO Market, by Product
1.4.3 Europe Advanced Therapy Medicinal Products CDMO Market, by Phase
1.4.4 Europe Advanced Therapy Medicinal Products CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan - 2022, Aug) Leading Players
Chapter 4. Europe Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 Europe Oncology Market by Country
4.2 Europe Cardiology Market by Country
4.3 Europe Central Nervous System & Musculoskeletal Market by Country
4.4 Europe Infectious Disease Market by Country
4.5 Europe Dermatology Market by Country
4.6 Europe Endocrine, Metabolic, Genetic Market by Country
4.7 Europe Immunology & Inflammation Market by Country
4.8 Europe Ophthalmology Market by Country
4.9 Europe Hematology Market by Country
4.1 Europe Gastroenterology Market by Country
4.11 Europe Others Market by Country
Chapter 5. Europe Advanced Therapy Medicinal Products CDMO Market by Product
5.1 Europe Gene Therapy Market by Country
5.2 Europe Cell Therapy Market by Country
5.3 Europe Tissue Engineered & Others Market by Country
Chapter 6. Europe Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 Europe Phase I Market by Country
6.2 Europe Phase II Market by Country
6.3 Europe Phase III Market by Country
6.4 Europe Phase IV Market by Country
Chapter 7. Europe Advanced Therapy Medicinal Products CDMO Market by Country
7.1 Germany Advanced Therapy Medicinal Products CDMO Market
7.1.1 Germany Advanced Therapy Medicinal Products CDMO Market by Indication
7.1.2 Germany Advanced Therapy Medicinal Products CDMO Market by Product
7.1.3 Germany Advanced Therapy Medicinal Products CDMO Market by Phase
7.2 UK Advanced Therapy Medicinal Products CDMO Market
7.2.1 UK Advanced Therapy Medicinal Products CDMO Market by Indication
7.2.2 UK Advanced Therapy Medicinal Products CDMO Market by Product
7.2.3 UK Advanced Therapy Medicinal Products CDMO Market by Phase
7.3 France Advanced Therapy Medicinal Products CDMO Market
7.3.1 France Advanced Therapy Medicinal Products CDMO Market by Indication
7.3.2 France Advanced Therapy Medicinal Products CDMO Market by Product
7.3.3 France Advanced Therapy Medicinal Products CDMO Market by Phase
7.4 Russia Advanced Therapy Medicinal Products CDMO Market
7.4.1 Russia Advanced Therapy Medicinal Products CDMO Market by Indication
7.4.2 Russia Advanced Therapy Medicinal Products CDMO Market by Product
7.4.3 Russia Advanced Therapy Medicinal Products CDMO Market by Phase
7.5 Spain Advanced Therapy Medicinal Products CDMO Market
7.5.1 Spain Advanced Therapy Medicinal Products CDMO Market by Indication
7.5.2 Spain Advanced Therapy Medicinal Products CDMO Market by Product
7.5.3 Spain Advanced Therapy Medicinal Products CDMO Market by Phase
7.6 Italy Advanced Therapy Medicinal Products CDMO Market
7.6.1 Italy Advanced Therapy Medicinal Products CDMO Market by Indication
7.6.2 Italy Advanced Therapy Medicinal Products CDMO Market by Product
7.6.3 Italy Advanced Therapy Medicinal Products CDMO Market by Phase
7.7 Rest of Europe Advanced Therapy Medicinal Products CDMO Market
7.7.1 Rest of Europe Advanced Therapy Medicinal Products CDMO Market by Indication
7.7.2 Rest of Europe Advanced Therapy Medicinal Products CDMO Market by Product
7.7.3 Rest of Europe Advanced Therapy Medicinal Products CDMO Market by Phase
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc. (Patheon, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 AGC Biologics, Inc. (AGC, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.2.5.3 Geographical Expansions:
8.3 Catalent, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Product Launches and Product Expansions:
8.5.4.2 Acquisition and Mergers:
8.5.4.3 Partnerships, Collaborations, and Agreements:
8.6 Lonza Group AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Geographical Expansions:
8.7 Celonic AG (JRS PHARMA GmbH & Co. KG)
8.7.1 Company Overview
8.8 Bio Elpida (Polyplus-transfection SA.)
8.8.1 Company Overview
8.9 Rentschler Biopharma SE
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Partnerships, Collaborations, and Agreements:
8.9.2.2 Acquisition and Mergers:
Companies Mentioned
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc.
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Methodology
LOADING...
